To further investigate the inhibitory effects of olverembatinib, we performed antiproliferation assays in primary SDH-deficient GIST cells and SDHB-knockout PC12#5F7 cells treated with olverembatinib and compared the results with those of agents that target various pathways: HIF-α (belzutifan, BAY 87-2243, PX-478); IGF-1R (linsitinib); VEGFR (sunitinib, regorafenib); and FGFR (rogaratinib, pemigatinib). This evidence concerns the gene IGF1R and gastrointestinal stromal tumor.